(AOF) – Abivax today announces the pricing of its securities for its IPO on the Nasdaq Global Market. This introduction will be made through a capital increase of 20,325,500 new ordinary shares, including a public offering of 18,699,460 ordinary shares in the form of American Depositary Shares (“ADS”), each representing the right to receive a common share, in the United States. The biotech specialist in chronic inflammatory diseases announces that this price has been set at $11.60 per ADS.
It corresponds to a price of 10.9864 euros per ordinary share. The total gross amount is estimated at approximately $235.8 million, equivalent to approximately €223.3 million. Settlement and delivery of the Global Offer would take place on October 24, 2023, subject to the usual conditions.
Abivax announced in mid-August its intention to make a public offering of its common shares in the United States.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
